Specific Therapeutic Benefits of Cannabidiol (CBD)
Post# of 75002
(Total Views: 308)
Posted On: 08/08/2018 1:37:50 PM
Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDAFont size: A | A | A
8:30 AM ET 8/8/18 | Dow Jones
NEW YORK, August 8, 2018 /PRNewswire/ --
CannabisNewsWire Editorial Coverage
In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).
-- FDA approval of a cannabis-based drug represents seismic political, legal
and economic shifts
-- Approval likely will lead to more clinical research and further
validation of CBD therapeutic efficacy
-- CBD market projected to explode to more than $2 billion in two years with
39 percent CAGR
What's most transformative about this drug approval is that this is the first time the FDA - the governmental arbiter of safe and effective medicine in the United States - has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.
CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD's mass appeal is that it's believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body's nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues, and chronic pain. It's being researched to treat Alzheimer's, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.
8:30 AM ET 8/8/18 | Dow Jones
NEW YORK, August 8, 2018 /PRNewswire/ --
CannabisNewsWire Editorial Coverage
In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).
-- FDA approval of a cannabis-based drug represents seismic political, legal
and economic shifts
-- Approval likely will lead to more clinical research and further
validation of CBD therapeutic efficacy
-- CBD market projected to explode to more than $2 billion in two years with
39 percent CAGR
What's most transformative about this drug approval is that this is the first time the FDA - the governmental arbiter of safe and effective medicine in the United States - has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.
CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD's mass appeal is that it's believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body's nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues, and chronic pain. It's being researched to treat Alzheimer's, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.
(4)
(0)Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links
Scroll down for more posts ▼